VIDEX EC 250 MG — DIN 02244598
DIDANOSINE : 250 MG · BRISTOL-MYERS SQUIBB CANADA · CAPSULE (ENTERIC-COATED) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is VIDEX EC?
VIDEX EC 250 MG contains DIDANOSINE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02244598, held by BRISTOL-MYERS SQUIBB CANADA, supplied as CAPSULE (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Apr-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does DIDANOSINE cost around the world?
DIDANOSINE is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 12 | 18 | ZAR███.██ |
| Morocco | PPV (public price) | 2 | 2 | MAD███.██ |
20 pack listings across 14 brand entries and 2 price bases, refreshed 05 Sep 2026. Ranges span every DIDANOSINE pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic DIDANOSINE in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing DIDANOSINE — 9 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB CANADA | 9 | 0 | VIDEX CHEWABLE DISPERSIBLE TAB 100MG, VIDEX CHEWABLE DISPERSIBLE TAB 150MG, VIDEX CHEWABLE DISPERSIBLE TAB 25MG, VIDEX CHEWABLE DISPERSIBLE TAB 50MG, VIDEX EC, VIDEX PEDIATRIC POWDER SOL 4G/BOTT | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | CAPSULE (ENTERIC-COATED) |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Didanosine |
|---|---|
| ATC code | J05AF02 |
| AHFS class | 08:18.08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02244598 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2244598 |
| Brand name | VIDEX EC |
| Generic / active ingredient | DIDANOSINE : 250 MG |
| Market authorization holder | BRISTOL-MYERS SQUIBB CANADA |
| Health Canada schedule | Prescription |
| ATC code | J05AF02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AF |
| Current status | CANCELLED POST MARKET |
| Status date | 02-Apr-2020 |
| Original market date | 2002-01-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| VIDEX CHEWABLE DISPERSIBLE TAB 100MG | 100 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 01940546 |
| VIDEX CHEWABLE DISPERSIBLE TAB 150MG | 150 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 01940554 |
| VIDEX CHEWABLE DISPERSIBLE TAB 25MG | 25 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 01940511 |
| VIDEX CHEWABLE DISPERSIBLE TAB 50MG | 50 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 01940538 |
| VIDEX EC | 400 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 02244599 |
| VIDEX EC | 125 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 02244596 |
| VIDEX EC | 200 MG | CAPSULE (ENTERIC-COATED) | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 02244597 |
| VIDEX PEDIATRIC POWDER SOL 4G/BOTT | 4 G | POWDER FOR SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | 01940635 |
2 · Same class — other molecules in ATC J05AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil | AG-TENOFOVIR · APO-TENOFOVIR · AURO-TENOFOVIR · JAMP-TENOFOVIR · MINT-TENOFOVIR · MYLAN-TENOFOVIR DISOPROXIL · NAT-TENOFOVIR · PMS-TENOFOVIR · RIVA-TENOFOVIR · TENOFOVIR · TEVA-TENOFOVIR · VIREAD | 13 | 13 | Yes |
| Entecavir | ACCEL-ENTECAVIR · APO-ENTECAVIR · AURO-ENTECAVIR · BARACLUDE · ENTECAVIR · ENTECAVIR TABLETS · JAMP ENTECAVIR · MINT-ENTECAVIR · PMS-ENTECAVIR · SANDOZ ENTECAVIR | 12 | 10 | Yes |
| Lamivudine | 3TC · APO-LAMIVUDINE · APO-LAMIVUDINE HBV · AURO-LAMIVUDINE · HEPTOVIR · JAMP LAMIVUDINE · JAMP LAMIVUDINE HBV · LAMIVUDINE ORAL SOLUTION | 14 | 9 | Yes |
| Zidovudine | APO-ZIDOVUDINE · NOVO-AZT CAP 100MG · RETROVIR (AZT) · RETROVIR (AZT) 300MG · ZIDOVUDINE ORAL SOLUTION USP | 7 | 3 | Yes |
| Abacavir | APO-ABACAVIR · MINT-ABACAVIR · ZIAGEN | 4 | 3 | Yes |
| Tenofovir Alafenamide | VEMLIDY | 1 | 1 | Yes |
| Didanosine | VIDEX CHEWABLE DISPERSIBLE TAB 100MG · VIDEX CHEWABLE DISPERSIBLE TAB 150MG · VIDEX CHEWABLE DISPERSIBLE TAB 25MG · VIDEX CHEWABLE DISPERSIBLE TAB 50MG · VIDEX EC · VIDEX PEDIATRIC POWDER SOL 4G/BOTT | 9 | 0 | Not in Canada |
| Stavudine | ZERIT · ZERIT - CAP 15MG · ZERIT - CAP 20MG · ZERIT - CAP 30MG · ZERIT - CAP 40MG | 5 | 0 | Not in Canada |
| Zalcitabine | HIVID TAB 0.375MG · HIVID TAB 0.75 MG | 2 | 0 | Not in Canada |
| Adefovir Dipivoxil | AA-ADEFOVIR · HEPSERA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · Remdesivir · Valaciclovir · Valganciclovir | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · Emtricitabine, Tenofovir Alafenamide And Bictegravir · Emtricitabine, Tenofovir Alafenamide And Rilpivirine · Emtricitabine, Tenofovir Alafenamide, Darunavir And Cobicistat · Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat · Emtricitabine, Tenofovir Disoproxil And Efavirenz · Emtricitabine, Tenofovir Disoproxil And Rilpivirine · Emtricitabine, Tenofovir Disoproxil, Elvitegravir And Cobicistat · Lamivudine And Abacavir · Lamivudine And Dolutegravir · Lamivudine, Abacavir And Dolutegravir · Lamivudine, Tenofovir Disoproxil And Doravirine · Lopinavir And Ritonavir · Tenofovir Disoproxil And Emtricitabine · Zidovudine And Lamivudine · Zidovudine, Lamivudine And Abacavir · Zidovudine, Lamivudine And Nevirapine | 56 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · Nelfinavir · Nirmatrelvir And Ritonavir · Ritonavir · Saquinavir · Tipranavir | 75 | 14 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · Lenacapavir · Letermovir · Maraviroc · Maribavir · Other Antivirals | 19 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · Rilpivirine | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · Glecaprevir And Pibrentasvir · Ombitasvir, Paritaprevir And Ritonavir · Ribavirin · Simeprevir · Sofosbuvir · Sofosbuvir And Ledipasvir · Sofosbuvir, Velpatasvir And Voxilaprevir · Telaprevir | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VIDEX EC called?
The same molecule, DIDANOSINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Videx | Latin | Morocco, South Africa |
| Aspen Didanosine | Latin | South Africa |
| DINEX | Latin | Morocco |
| Videx paed | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.